KHKaitlin R. Hulce

Kaitlin R. Hulce

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kaitlin R. Hulce has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Single-particle Cryo Electron Microscopy of Human Cytomegalovirus Protease Bound to an Inhibitory Antibody Fragment

    by Zimanyi M, Hulce Kr, Bohn M, Norman J, Rohweder Pj, Cheng Y, Craik Cs, Detomasi Tc

  • Open Access

    Antibody Reveals Conformational Latch Controlling Herpesvirus Proteases

    by Marcell Zimanyi, Kaitlin R. Hulce, Markus-Frederik Bohn, Jordan Norman, Peter J. Rohweder, Yifan Cheng, Charles S. Craik

    Human herpesviruses (HHVs) are widespread pathogens that cause severe disease. Their replication depends on the HHV protease (HHV Pr), an enzyme essential for capsid maturation. Because HHV Pr must dimerize to become catalytically active, disrupting dimer formation is a promising strategy for antiviral therapeutic development. We isolated a conformationally selective antibody inhibitor, Fab5, from a fully human naïve Fab-phage library that recognizes monomeric human cytomegalovirus protease (HCMV Pr). A 2.6 Å cryoelectron microscopy (cryo-EM) structure of the Fab5-HCMV Pr complex revealed that Fab5 binds a flexible loop distal from the active site and dimer interface which we call the latch loop. In HCMV Pr dimers, this loop secures the C-terminal tail to the protein core. Structure-guided mutagenesis confirmed that the latch loop is essential for HCMV Pr dimerization and activity. This loop is structurally conserved across all HHV Prs, and we show its functional role in Kaposi’s Sarcoma-associated herpesvirus (KSHV) Pr as well. The latch loop plays a mechanistic role in the conformational transition required for HHV Pr activity, and it forms a cryptic site that presents a new avenue for future allosteric inhibitor development.


  • Open Access

    Mechanisms of AAV neutralization by human alpha-defensins

    by Jessica M. Porter, Kaitlin R. Hulce, Mackenzi S. Oswald, Kevin Busuttil, Shanan N. Emmanuel, Antonette Bennett, Robert McKenna, Jason G. Smith

    Antiviral immunity compromises the efficacy of adeno-associated virus (AAV) vectors used for gene therapy. This is well understood for the adaptive immune response. However, innate immune effectors like alpha-defensin antimicrobial peptides also block AAV infection, although their mechanisms of action are unknown. To address this gap in knowledge, we investigated AAV2 and AAV6 neutralization by human neutrophil peptide 1 (HNP1), a myeloid alpha-defensin, and human defensin 5 (HD5), an enteric alpha-defensin. We found that both defensins bind to AAV2 and inhibit infection at low micromolar concentrations, similar to our prior studies of AAV6. While HD5 prevents AAV2 and AAV6 from binding to cells, HNP1 does not. However, AAV2 and AAV6 exposed to HD5 after binding to cells are still neutralized, indicating an additional block to infection. Accordingly, both HD5 and HNP1 inhibit externalization of the VP1 unique domain of both AAV2 and AAV6, which contains a phospholipase A 2 enzyme required for endosome escape and nuclear localization signals required for nuclear entry. Consequently, both defensins prevent AAV from reaching the nucleus. Disruption of intracellular trafficking of the viral genome to the nucleus is reminiscent of how alpha-defensins neutralize other non-enveloped viruses, suggesting a common mechanism of inhibition. These results will inform the development of vectors capable of overcoming these hurdles to improve the efficiency of gene therapy. Author Summary: AAVs are commonly used as gene therapy vectors due to their broad tropism and lack of disease association; however, host innate immune factors, such as human alpha-defensin antimicrobial peptides, can hinder gene delivery. Although it is becoming increasingly evident that human alpha-defensins can block infection by a wide range of nonenveloped viruses, including AAVs, their mechanism of action remains poorly understood. In this study, we describe for the first time how two types of abundant human alpha-defensins neutralize two AAV serotypes, AAV2 and AAV6. We found that one defensin prevents AAV binding to cells, the first step in infection, while both defensins block a critical later step in AAV entry. Our findings support the emerging idea that defensins use a common strategy to block infection by DNA viruses that replicate in the nucleus. Through understanding how innate immune effectors interact with and impede AAV infection, vectors can be developed to bypass these interventions and allow more efficient gene delivery.

  • Open Access

    Inhibiting a dynamic viral protease by targeting a non-catalytic cysteine

    by Kaitlin R. Hulce, Priyadarshini Jaishankar, Gregory M. Lee, Markus-Frederik Bohn, Emily J. Connelly, Kristin Wucherer, Chayanid Ongpipattanakul, Regan F. Volk, Shih-Wei Chuo, Michelle R. Arkin, et al.